Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April 22-23 Quantitative risk analysis using exposure-response.

Slides:

Advertisements

Similar presentations

What is Pharmacometrics (PM)?

Advertisements

Matthew M. Riggs, Ph.D. metrum research group LLC

The ICH E5 Guidance: An Update on Experiences with its Implementation The ICH E5 Guidance: An Update on Experiences with its Implementation Robert T. O’Neill,

December 14, FDA Advisory Committee for Pharmaceutical Science Nonclinical Studies Subcommittee Efficient advancement to clinical trials Jack A.

Assessment of Adalimumab Dose Selection for Adult Ulcerative Colitis Using Exposure-Response Analyses Michael Bewernitz1, Christine Garnett2,4, Klaus Gottlieb3,

1 PK/PD modeling within regulatory submissions Is it used? Can it be used and if yes, where? Views from industry 24 September 2008.

Bioequivalence of Highly Variable (HV) Drugs: Clinical Implications Why HV Drugs are Safer Leslie Z. Benet, Ph.D. Professor of Biopharmaceutical Sciences.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.

+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.

Neonatal/Juvenile Animal Safety Studies Kenneth L. Hastings, Dr.P.H., D.A.B.T. Office of New Drugs, CDER.

Effectiveness Evaluation for Therapeutic Drugs for Non-Food Animals

Clinical Pharmacology Overview From the Antiviral Perspective Kellie Schoolar Reynolds, Pharm.D. Pharmacokinetics Team Leader Office of Clinical Pharmacology.

Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April 22, 2003 Pediatric Population Pharmacokinetics Study.

Trastuzumab [Genentech Inc.] Labeling Supplement to Include FISH Testing as a Method to Select Patients for Treatment FDA Clinical Review December 5, 2001.

Individual Bioequivalence Lawrence J. Lesko, Ph.D. Director Office of Clinical Pharmacology and Biopharmaceutics Advisory Committee for Pharmaceutical.

FDA Nasal BA/BE Guidance Overview

Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.

Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.

Integrating Scientific Advances into Regulation: Pharmacogenomics and Pharmacogenetics Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research.

Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.

Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 In Vitro/Animal Models to Support Dosage Selection: FDA Perspective.

Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.

Clinical Pharmacy Part 2

Quality Systems for Clinical Pharmacology and Biopharmaceutics Review Lawrence J. Lesko, Ph.D. Director, Office of Clinical Pharmacology and Biopharmaceutics.

Joint Meeting of Anti-Infective Drugs & Drug Safety and Risk Management Advisory Committees December 14-15, 2006 Ketek  (telithromycin) Regulatory History.

Drug Transfer Into Breast Milk and Interpretation of Data Lawrence J. Lesko Office of Clinical Pharmacology and Biopharmaceutics Center for Drug Evaluation.

1 Axcan Public Presentation for the FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting July 23, 2008.

1 QT Evaluation Studies: Pharmacometric Considerations Leslie Kenna, Peter Lee and Yaning Wang Office of Clinical Pharmacology and Biopharmaceutics CDER/FDA.

FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.

Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.

Update: Topics Previously Presented to the CPSC Clinical Pharmacology Subcommittee (CPSC) of the Advisory Committee for Pharmaceutical Science November.

The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.

History of Pediatric Labeling

1 Nonprescription Drugs AC Meeting March 23, 2005 Efficacy of OTC Healthcare Antiseptics: Introduction to the Regulatory Issues Susan S. Johnson, Pharm.D.,

Inclusion of Women in Clinical Trials & Drug Development Regulatory Perspective Ameeta Parekh, Ph.D. R&D Director Office of Women’s Health Food & Drug.

Use of Biomarker Information in Drug Product Labels to Individualize Pharmacotherapy Lawrence J. Lesko, Ph.D., FCP Director of the Office of Clinical Pharmacology.

1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.

DOSE SELECTION FOR ANTI-INFECTIVE DRUGS: INDUSTRY PERSPECTIVE

1 METHODS FOR DETERMINING SIMILARITY OF EXPOSURE-RESPONSE BETWEEN PEDIATRIC AND ADULT POPULATIONS Stella G. Machado, Ph.D. Quantitative Methods and Research.

Phase I Issues for Novel TB Drugs Dakshina M. Chilukuri, Ph.D. Office of Clinical Pharmacology and Biopharmaceutics, FDA OPEN FORUM ON KEY ISSUES IN TB.

July FUTURE of PHASE 1, 2, and 3 TRIALS Philip Colangelo, Pharm.D., Ph.D. Office of Clinical Pharmacology & Biopharmaceutics FDA / CDER.

1 Operation of the Prescription Drug User Fee Program Janet Woodcock, M.D. Deputy Commissioner for Operations November 14, 2005.

Clinical Pharmacology Subcommittee (CPSC) Report ACPS Presentation, April 13, 2004 Jürgen Venitz, MD, Ph.D. Goals of the Advisory Subcommittee: To provide.

General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,

Systemic Exposure of Topical Tacrolimus Veneeta Tandon, Ph.D. Pharmacokinetics Reviewer Division of Pharmaceutical Evaluation III Office of Clinical Pharmacology.

HIV-1 Resistance Testing in Drug Development Antiviral Drugs Advisory Committee Meeting November 2-3, 1999.

Ameeta Parekh, Ph.D. CDER/OCPB CPSC Meeting November 17/18

Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,

Initiatives Drive Pediatric Drug Development January 30, 2002.

Biotechnology Industry Organization (BIO) Risk Management Public Workshop Day 1 - April 9, 2003 Risk Assessment in Drug and Biological Development Joanna.

Applying New Science to Drug Safety Janet Woodcock, M.D. Acting Deputy Commissioner for Operations April 15, 2005.

1 The Role of Exposure-Response Evaluation in Drug Development and Regulatory Decisions Case Study: Rosuvastatin Hae-Young Ahn, Ph.D. Office of Clinical.

Questions to Committee about Potential Cancer Risk with Use of Topical Immunosuppressants (Calcineurin Inhibitors) Question 1: Messages about Risk A. Based.

Bioequivalence Criteria Research Plan Stella G. Machado, Ph.D. Office of Biostatistics and the Replicate Design Technical Committee Advisory Committee.

Pharmacogenetics (PGx) of Irinotecan: Scientific and Clinical Impact of UGT Polymorphism: Background Clinical Pharmacology Subcommittee of ACPS November.

1 Pharmacokinetic Information Submitted to Support Valganciclovir Use in Maintenance Therapy for CMV Retinitis Robert O. Kumi, Ph.D. Reviewer, Pharmacokinetics.

Clinical Trials - PHASE II. Introduction  Important part of drug discovery process  Why important??  Therapeutic exploratory trial  First time in.

Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 Current Status of Dose Selection in Antimicrobial Drug Development.

1 Biopharmaceutics Dr Mohammad Issa Saleh. 2 Biopharmaceutics Biopharmaceutics is the science that examines this interrelationship of the physicochemical.

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT Ramana S. Uppoor, R.Ph., Ph.D. Division of Clinical Pharmacology-1 Office of Clinical Pharmacology, CDER, FDA.

Topic #1: EOP2A Meetings Please comment on the goals of the proposed EOP2A meeting and the impact that such meetings could have on optimizing dose selection.

Methods to Adjust Doses Based on Exposure-Response Information Points to Consider Richard Lalonde Clinical Pharmacokinetics and Pharmacodynamics Pfizer.

Regulatory Considerations for Approval: FDA perspective

Patient Focused Drug Development An FDA Perspective

Prof. Dr. Basavaraj K. Nanjwade

Biopharmaceutics Dr Mohammad Issa Saleh.

بسم الله الرّحمن الرّحيم. Dr Sima Sadrai TUMS

Assessing similarity of curves: An application in assessing similarity between pediatric and adult exposure-response curves July 31, 2019 Yodit Seifu,

Presentation transcript:

Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April Quantitative risk analysis using exposure-response for determining dose adjustment for special populations Peter I. Lee, PhD Associate Director, Pharmacometrics Office of Clinical Pharmacology and Biopharmaceutics

Main Topics Discussed in the Last Meeting A standardized approach for evaluating the need of dose adjustment in special populations using exposure-response information. A regulatory decision tree for dose adjustment recommendations. Potential applications of utility function for risk and benefit assessment.

Topics for This Session Examples of standardized approach for using exposure-response information to adjust doses in special populations. Population PK/PD approach for evaluating needs of dose adjustment in special populations. An example of applying utility function for optimal dosing strategy.

Background Information: Dose Adjustments in Special Populations NDAs may contain up to 20 or more clinical pharmacology studies. Intrinsic/extrinsic factors result in increases or decreases in exposure due to change in pharmacokinetics. Need a consistent approach to determine dosing adjustment in special populations.

An Example of Changes in Exposure Due to Intrinsic and Extrinsic Factors: When Should Dose be Adjusted ? Change in AUC Difference in AUC

Issues Related to Dosing Adjustment in Drug Labels of NDA Submissions Inconsistency in dosing adjustments is frequently seen in initial label language of NDA submissions. Exposure-response information needed for rational dosing adjustment is sometimes incomplete or unavailable in the NDAs. Additional exposure-response analyses are usually required and conducted by FDA reviewers to address questions of dosing adjustments. Standard for analyzing and interpreting exposure- response data for safety and effectiveness assessments of drugs would be beneficial to decision-making.

To Improve the Current Status, We Propose To... Develop and evaluate a standardized approach for reviewers and, possibly, industry to quantitatively assess the impact of exposure change on either safety or efficacy that result from change in pharmacokinetics due to intrinsic or extrinsic factors.

Proposed Standardized Approach: Estimating the Probability of Response Exposure Response Variable Frequency reftest E+  Response Frequency reftest Probability of clinical significant response = Exposure

Interpreting The Clinical Significance of PK Change Observed data –PK in special populations –PK/PD relationship Estimate the percentage (probability) in the patient population with the response > the clinically significant “critical value”. Determine the “critical value” of response based on risk and benefit assessment of the drug therapy –case-by-case basis –utility functions

Decision Tree for Dosing Adjustment Recommendations Is PK/PD available ? Whether the PK change is clinically significant based on E-R ? (Standardized Approach) If the 90% CI of test/ref is within the default “no effect boundaries” No dose adjustment Dosing adjustment, precaution, or warning yn y n Refer to specific guidance to recommend labeling language y n

Examples to be Discussed Today To illustrate the use of the proposed standardized approach for estimating the probability of toxicity in special populations to determine the need of dose adjustment. To illustrate the potential utility of population analyses to obtain exposure- response information from large efficacy/safety trials. To demonstrate a method for applying utility functions to optimize dosing strategy.

Speakers in this Session Dr. Nhi Nguyen, DPE1, OCPB Dr. Jenny J. Zheng, DPE3, OCPB Dr. He Sun, DPE2, OCPB Dr. Mats Karlsson, Uppsala University

Questions to the Committee The standardized approach –Under what treatment circumstances (e.g.: intrinsic/extrinsic factors or therapeutic areas) would this standardized approach not be applicable ? –Does exposure-response differ between special and typical populations? If so, how can the differences be detected?

Questions to the Committee (cont.) Population PK/PD –What are the utility and general limitations of linking PK obtained from population analysis to response endpoints ? –What are the general considerations in E-R based dose adjustment for special populations ?

Questions to the Committee (cont.) Utility functions –Can the presented approach of utility function be generalized to other scenarios?